Hoth Therapeutics, Inc. (HOTH) has announced a definitive agreement to sell 2.85 million shares at $0.70 each, generating gross proceeds of $2 million in a registered direct offering. Concurrently, the company is issuing unregistered warrants to purchase up to 2.86 million shares at an exercise price of $0.85, potentially raising an additional $2.4 million if fully exercised. The proceeds will be allocated for general corporate purposes, including working capital, with the offering expected to close around April 2, 2026.
This capital raise comes at a time when Hoth’s stock has seen significant volatility, closing at $0.54 after a steep decline of 34.86%. The company’s lead candidate, HT-001, is currently in a Phase II trial targeting skin disorders related to cancer therapies, which could be pivotal for future growth and investor interest.
For market professionals, the key takeaway is the potential dilution from the warrants and the need to monitor Hoth’s clinical progress closely, as it could significantly impact stock performance in the coming months.
Source: nasdaq.com